Lilly Bracing For Possible Medicare Non-Coverage Or CED Decision On Amyvid
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly executives discuss likely outcomes of a pending CMS draft decision on Medicare coverage for the beta amyloid imaging agent Amyvid, emphasizing that a decision for non-coverage or coverage with evidence development would be a major setback for research and development in Alzheimer’s disease.
You may also be interested in...
Medicare Coverage Decision For Amyvid Due July 2013
At Lilly’s request, CMS has agreed to consider expanding the positron imaging tomography tracers that can be covered by Medicare to include agents for imaging beta-amyloid plaques when diagnosing dementia and other neurodegenerative disease.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.